Format

Send to

Choose Destination
See comment in PubMed Commons below
Allergy. 2012 Jun;67(6):741-3. doi: 10.1111/j.1398-9995.2012.02815.x. Epub 2012 Apr 5.

A prospective study on the safety of sublingual immunotherapy in pregnancy.

Author information

1
Allergist and Asthmologist, Department of Clinical Allergy and Asthma, Allergy and Asthma Clinic, Bombay, India. drwiqar@gmail.com

Abstract

BACKGROUND:

The aim of this study was to determine the safety of sublingual immunotherapy in pregnancy, which has not yet been reported.

METHODS:

One hundred and fifty-five patients received sublingual immunotherapy with either house dust mite (D. farinae) or a mixture of up to five allergens during 185 pregnancies. Twenty-four patients received sublingual immunotherapy for the first time during pregnancy. Follow-up data were analysed with regard to abortion, perinatal mortality, prematurity, toxaemia and congenital malformation. Two control groups did not receive immunotherapy; group A (85 patients) received budesonide 400 μg twice daily and group B (40 patients) received rescue salbutamol inhalation. All three groups were on appropriate avoidance measures.

RESULTS:

Six-year follow-up data for the sublingual immunotherapy group revealed an incidence of complications less than that in the general population and a higher incidence of complications in both control groups.

CONCLUSIONS:

This study concludes that sublingual immunotherapy is safe during pregnancy and is also safe when initiated for the first time in a pregnant patient.

[Indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wiley
    Loading ...
    Support Center